Conversion from Standard Opioid Therapy to Once-daily Oral Extended-release Hydromorphone in Patients with Chronic Cancer Pain

Author： Wallace M   Rauck RL   Moulin D   Thipphawong J   Khanna S   Tudor IC  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.36, Iss.2, 2008-03, pp. : 343-352

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Patient Preference Study Comparing Two Extended-Release Morphine Sulfate Formulations (Once-Daily Kadian versus Twice-Daily MS Contin) for Cancer Pain

By Kerr R.O.  

Clinical Drug Investigation, Vol. 19, Iss. 1, 2000-01 ,pp. : 25-32

Adis International

Access to resources Recommend Favorite

Pharmacokinetic profile of once-daily cyclobenzaprine extended-release

By Darwish Mona   Hellriegel Edward T  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 11, 2010-11 ,pp. : 1425-1436

Informa Healthcare

Access to resources Recommend Favorite

Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease

By Perez Lloret Santiago   Rascol Olivier  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 13, 2010-09 ,pp. : 2221-2230

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Once-Daily Molsidomine: From Immediate-Release to Prolonged-Release Once-Daily Formulations

By Herchuelz A.  

American Journal of Drug Delivery, Vol. 2, Iss. 2, 2004-01 ,pp. : 131-141

Adis International

Access to resources Recommend Favorite

Extended-release (ER) nalbuphine may have potential in patients with chronic pain secondary to osteoarthritis of the knee or hip

By  

Inpharma, Vol. 1, Iss. 1625, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite